Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H4ClNO2 |
Molecular Weight | 169.5654 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cc2c(cc1Cl)nc(O)o2
InChI
InChIKey=TZFWDZFKRBELIQ-UHFFFAOYSA-N
InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
Molecular Formula | C7H4ClNO2 |
Molecular Weight | 169.5654 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.rxlist.com/chlorzoxazone-drug.htmCurator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68002753
Sources: http://www.rxlist.com/chlorzoxazone-drug.htm
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68002753
Chlorzoxazone is a centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles. Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.
CNS Activity
Originator
Sources: https://www.google.com/patents/US2895877
Curator's Comment:: Marsh, D.F.; US. Patent 2,895,877; July 21, 1959; assigned to McNeil Laboratories, Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4305 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10712246 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CHLORZOXAZONE Approved UseINDICATIONS & USAGE SECTION Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man. Launch Date5.7870719E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6631711/ |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: QUERCETIN |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.45 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
12.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
0.14 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: QUERCETIN |
6-HYDROXYCHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
6-HYDROXYCHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4084 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6631711/ |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16.69 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: QUERCETIN |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.86 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
43.5 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
15.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
32.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
0.64 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: QUERCETIN |
6-HYDROXYCHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.95 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
6-HYDROXYCHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6631711/ |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.65 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: QUERCETIN |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.21 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28983678/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.9% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3.2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12534643/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORZOXAZONE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/25815637/ Page: 7.0 |
major | |||
Page: 1.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25815637/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25815637/ Page: 7.0 |
minor |
PubMed
Title | Date | PubMed |
---|---|---|
EBIO, an agent causing maintained epithelial chloride secretion by co-ordinate actions at both apical and basolateral membranes. | 2001 |
|
Chlorzoxazone: a probe drug the metabolism of which can be used to monitor one-point blood sampling in the carbon tetrachloride-intoxicated rat. | 2001 Aug |
|
Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. | 2001 Dec 15 |
|
Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. | 2001 Feb |
|
Characterization of xenobiotic-metabolizing cytochrome P450 (CYP) forms in ringed and grey seals from the Baltic Sea and reference sites. | 2001 Jan |
|
One hundred percent online identity check of pharmaceutical products by near-infrared spectroscopy on the packaging line. | 2001 Jan |
|
Synthetic chloride channel restores glutathione secretion in cystic fibrosis airway epithelia. | 2001 Jul |
|
Spectrofluorometric determination of ibuprofen in pharmaceutical formulations. | 2001 Jun |
|
Genetic and dietary factors affecting human metabolism of 1,3-butadiene. | 2001 Jun 1 |
|
Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. | 2001 Mar |
|
In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. | 2001 Mar |
|
Mitochondrial dysfunction by gamma-irradiation accompanies the induction of cytochrome P450 2E1 (CYP2E1) in rat liver. | 2001 Mar 21 |
|
Toxicity and effects of 2,6-di-tert-butyl-4-methylphenyl N-methylcarbamate (terbutol) on hepatic cytochrome P450 in F344 rats. | 2001 Nov |
|
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). | 2001 Nov |
|
Assessment of cytochrome P450 activity by a five-drug cocktail approach. | 2001 Nov |
|
The effect of endotoxin on hepatocyte nuclear factor 1 nuclear protein binding: potential implications on CYP2E1 expression in the rat. | 2001 Oct |
|
Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. | 2002 Feb |
|
Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. | 2002 Jan |
|
Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. | 2002 Mar |
|
The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. | 2002 Mar |
|
Inhibition of cytochromes P450 by antifungal imidazole derivatives. | 2002 Mar |
|
Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. | 2002 Oct |
|
Cytochrome P4502E1 phenotyping by the measurement of the chlorzoxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene. | 2002 Sep |
|
Kinetic study of alkaline induced hydrolysis of the skeletal muscle relaxant chlorzoxazone using ratio spectra first derivative spectrophotometry. | 2003 Apr |
|
The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. | 2003 Apr |
|
Lipopolysaccharide-mediated modulation of cytochromes P450 in Stat1 null mice. | 2003 Apr |
|
Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. | 2003 Apr 24 |
|
Phorbol ester induces CYP2E1 in astrocytes, through a protein kinase C- and tyrosine kinase-dependent mechanism. | 2003 Aug |
|
Effects of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. | 2003 Aug |
|
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. | 2003 Aug |
|
Rates of metabolism of chlorzoxazone, dextromethorphan, 7-ethoxycoumarin, imipramine, quinidine, testosterone and verapamil by fresh and cryopreserved rat liver slices, and some comparisons with microsomes. | 2003 Aug |
|
Characterization of vectorial chloride transport pathways in the human pancreatic duct adenocarcinoma cell line HPAF. | 2003 Aug |
|
Simultaneous determination of aspirin and isosorbide 5-mononitrate in formulation by reversed phase high pressure liquid chromatography. | 2003 Aug 21 |
|
Study of the fragmentation mechanism of protonated 6-hydroxychlorzoxazone: application in simultaneous analysis of CYP2E1 activity with major human cytochrome P450s. | 2003 Feb 1 |
|
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | 2003 Jan 1 |
|
Maintenance of liver functions in rat hepatocytes cultured as spheroids in a rotating wall vessel. | 2003 Jan-Feb |
|
Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. | 2003 Jul 18 |
|
Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome p4501A2. | 2003 Jun |
|
Functional characterization of three human cytochrome p450 2E1 variants with amino acid substitutions. | 2003 Jun |
|
How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? | 2003 Jun |
|
Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. | 2003 Jun |
|
Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. | 2003 Jun 6 |
|
Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. | 2003 Mar |
|
Pharmacokinetics of intravenous chlorzoxazone in rats with dehydration and rehydration: effects of food intakes. | 2003 Mar |
|
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. | 2003 Mar |
|
Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. | 2003 Nov |
|
Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. | 2003 Nov |
|
GYKI-47261, a new AMPA [2-amino-3-(3-hydroxymethylisoxazole-4-yl)propionic acid] antagonist, is a CYP2E1 inducer. | 2003 Nov |
|
CYP2E1 regulation by benzene and other small organic chemicals in rat liver and peripheral lymphocytes. | 2003 Sep 15 |
|
ATP release triggered by activation of the Ca2+-activated K+ channel in human airway Calu-3 cells. | 2004 Mar |
Patents
Sample Use Guides
One tablet three or four times daily. If adequate response is not obtained with this dose, it may be increased to one and one-half tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16859676
Chlorzoxazone did not affect the tension of the rat thoracic artery rings at rest, but relaxed the precontraction induced by 1 uM noradrenaline in an endothelium independent manner. Preincubation with chlorzoxazone also antagonized the contraction induced by 1 uM noradrenaline or 25 mM KCl.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:58:15 UTC 2021
by
admin
on
Fri Jun 25 20:58:15 UTC 2021
|
Record UNII |
H0DE420U8G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
200
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
NDF-RT |
N0000175737
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
WHO-VATC |
QM03BB53
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
WHO-ATC |
M03BB03
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
WHO-VATC |
QM03BB03
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
WHO-ATC |
M03BB53
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
NDF-RT |
N0000175730
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
WHO-ATC |
M03BB73
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
||
|
WHO-VATC |
QM03BB73
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
202-403-9
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
95-25-0
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
D002753
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
1130505
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | USP-RS | ||
|
H0DE420U8G
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
2322
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
95-25-0
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
SUB06215MIG
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
CHLORZOXAZONE
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
2410
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | RxNorm | ||
|
CHEMBL1371
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
748
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
M3471
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | Merck Index | ||
|
C28926
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
626
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
2733
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY | |||
|
DB00356
Created by
admin on Fri Jun 25 20:58:15 UTC 2021 , Edited by admin on Fri Jun 25 20:58:15 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
EXCRETED UNCHANGED |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
further metabolized to glucoronide
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Cmax | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION PHARMACOKINETIC PHARMACOKINETIC |
|
||
Tmax | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION PHARMACOKINETIC PHARMACOKINETIC |
|
||